<?xml version="1.0" encoding="UTF-8"?>
<ref id="B108-pharmaceuticals-13-00096">
 <label>108.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yao</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Ye</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Cui</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Niu</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Dong</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Song</surname>
    <given-names>C.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2)</article-title>
  <source>Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1093/cid/ciaa237</pub-id>
 </element-citation>
</ref>
